European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer Biotech Investing
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain Pharmaceutical Investing
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics Biotech Investing
Notice of Lead Plaintiff Deadline for Shareholders in the BELLUS Health Inc. Class Action Lawsuit Biotech Investing
BioHarvest Sciences Inc. Adds Global Marketing Expert Scott McCune to Advisory Board Biotech Investing
Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival Biotech Investing
Real-World Evidence Supports Effectiveness of First-line IBRANCE® Combination Therapy in HR+, HER2- Metastatic Breast Cancer Pharmaceutical Investing
ALERT FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
